|
1
|
de Krijger I, Mekenkamp LJ, Punt CJ and
Nagtegaal ID: MicroRNAs in colorectal cancer metastasis. J Pathol.
224:438–447. 2011.
|
|
2
|
Xu AG, Yu ZJ, Jiang B, et al: Colorectal
cancer in Guangdong Province of China: a demographic and anatomic
survey. World J Gastroenterol. 16:960–965. 2010.
|
|
3
|
Zlobec I and Lugli A: Invasive front of
colorectal cancer: dynamic interface of pro-/anti-tumor factors.
World J Gastroenterol. 15:5898–5906. 2009.
|
|
4
|
Natalwala A, Spychal R and Tselepis C:
Epithelial-mesenchymal transition mediated tumourigenesis in the
gastrointestinal tract. World J Gastroenterol. 14:3792–3797.
2008.
|
|
5
|
Brabletz T, Jung A, Hermann K, et al:
Nuclear overexpression of the oncoprotein beta-catenin in
colorectal cancer is localized predominantly at the invasion front.
Pathol Res Pract. 194:701–704. 1998.
|
|
6
|
Guarino M, Rubino B and Ballabio G: The
role of epithelial-mesenchymal transition in cancer pathology.
Pathology. 39:305–318. 2007.
|
|
7
|
Sánchez-Tilló E, de Barrios O, Siles L,
Cuatrecasas M, Castells A and Postigo A: Beta-catenin/TCF4 complex
induces the epithelial-to-mesenchymal transition (EMT)-activator
ZEB1 to regulate tumor invasiveness. Proc Natl Acad Sci USA.
108:19204–19209. 2011.
|
|
8
|
Jang TJ: Expression of E-cadherin and
β-catenin is altered at tumor budding sites, whose number is
associated with the progression of colorectal carcinoma. Korean J
Pathol. 43:523–527. 2009.
|
|
9
|
International Agency for Research on
Cancer. World Health Organization classification of tumours.
Pathology and genetics of tumours of the digestive system. IARC
Press; Lyon, France: 2000
|
|
10
|
Edge SBD and Compton C: AJCC Cancer
Staging Manual. 7th edition. JAMA. 304. pp. 1726–1727. 2010
|
|
11
|
Ru GQ, Wang HJ, Xu WJ and Zhao ZS:
Upregulation of Twist in gastric carcinoma associated with tumor
invasion and poor prognosis. Pathol Oncol Res. 17:341–347.
2011.
|
|
12
|
Sinicrope FA, Ruan SB, Cleary KR, et al:
bcl-2 and p53 oncoprotein expression during colorectal
tumorigenesis. Cancer Res. 55:237–241. 1995.
|
|
13
|
Zhu JL, Song YX, Wang ZN, et al: The
clinical significance of mesenchyme forkhead 1 (FoxC2) in gastric
carcinoma. Histopathology. 62:1038–1048. 2013.
|
|
14
|
Boo YJ, Park JM, Kim J, et al: L1
expression as a marker for poor prognosis, tumor progression, and
short survival in patients with colorectal cancer. Ann Surg Oncol.
14:1703–1711. 2007.
|
|
15
|
Baldus SE, Mönig SP, Huxel S, et al: MUC1
and nuclear beta-catenin are coexpressed at the invasion front of
colorectal carcinomas and are both correlated with tumor prognosis.
Clin Cancer Res. 10:2790–2796. 2004.
|
|
16
|
Grünert S, Jechlinger M and Beug H:
Diverse cellular and molecular mechanisms contribute to epithelial
plasticity and metastasis. Nat Rev Mol Cell Biol. 4:657–665.
2003.
|
|
17
|
Hugo H, Ackland ML, Blick T, et al:
Epithelial-mesenchymal and mesenchymal-epithelial transitions in
carcinoma progression. J Cell Physiol. 213:374–383. 2007.
|
|
18
|
Conacci-Sorrell M, Simcha I, Ben-Yedidia
T, et al: Autoregulation of E-cadherin expression by
cadherin-cadherin interactions: the roles of beta-catenin
signaling, Slug, and MAPK. J Cell Biol. 163:847–857. 2003.
|
|
19
|
Gavert N and Ben-Ze’ev A:
Epithelial-mesenchymal transition and the invasive potential of
tumors. Trends Mol Med. 14:199–209. 2008.
|
|
20
|
Mårtensson A, Oberg A, Jung A, et al:
Beta-catenin expression in relation to genetic instability and
prognosis in colorectal cancer. Oncol Rep. 17:447–452. 2007.
|
|
21
|
Chen Z, He X, Jia M, et al: Beta-catenin
overexpression in the nucleus predicts progress disease and
unfavourable survival in colorectal cancer: a meta-analysis. PloS
One. 8:e638542013.
|
|
22
|
Hörkkö TT, Klintrup K, Mäkinen JM, et al:
Budding invasive margin and prognosis in colorectal cancer - no
direct association with beta-catenin expression. Eur J Cancer.
42:964–971. 2006.
|
|
23
|
Roca F, Mauro LV, Morandi A, et al:
Prognostic value of E-cadherin, beta-catenin, MMPs (7 and 9), and
TIMPs (1 and 2) in patients with colorectal carcinoma. J Surg
Oncol. 93:151–160. 2006.
|
|
24
|
Lee SJ, Choi SY, Kim WJ, et al: Combined
aberrant expression of E-cadherin and S100A4, but not beta-catenin
is associated with disease-free survival and overall survival in
colorectal cancer patients. Diagn Pathol. 8:992013.
|
|
25
|
Wangefjord S, Brändstedt J, Lindquist KE,
et al: Associations of beta-catenin alterations and MSI screening
status with expression of key cell cycle regulating proteins and
survival from colorectal cancer. Diagn Pathol. 8:102013.
|
